Swedish Orphan Biovitrum AB (SOBIN) Stock Statistics & Valuation Metrics
Total Valuation
Swedish Orphan Biovitrum AB has a market cap or net worth of $323.71B. The enterprise value is $169.97B.
- Market Cap
- $323.71B
- Enterprise Value
- $169.97B
Share Statistics
Swedish Orphan Biovitrum AB has 357,636,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 357,636,500
- Owned by Insiders
- ―
- Owned by Institutions
- 10.93%
Financial Efficiency
Swedish Orphan Biovitrum AB’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 14.02%.
- Return on Equity (ROE)
- 0.01
- Return on Assets (ROA)
- 0.01
- Return on Invested Capital (ROIC)
- 14.02%
- Return on Capital Employed (ROCE)
- 0.16
- Revenue Per Employee
- 13.33M
- Profits Per Employee
- 225.58K
- Employee Count
- 2,119
- Asset Turnover
- 0.42
- Inventory Turnover
- 3.10
Valuation Ratios
The current PE Ratio of Swedish Orphan Biovitrum AB is 25.62. Swedish Orphan Biovitrum AB’s PEG ratio is 0.00.
- PE Ratio
- 25.62
- PS Ratio
- 5.34
- PB Ratio
- 3.75
- Price to FCF
- 23.42
- Price to Operating Cash Flow
- 21.61
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Swedish Orphan Biovitrum AB had revenue of 28.24B and earned 478.00M in profits. Earnings per share was 1.39.
- Revenue
- 28.24B
- Gross Profit
- 12.32B
- Operating Income
- 8.05B
- Pretax Income
- 34.00M
- Net Income
- 478.00M
- EBITDA
- 10.96B
- Earnings Per Share (EPS)
- 1.39
Cash Flow
In the last 12 months, operating cash flow was 7.89B and capital expenditures -604.00M, giving a free cash flow of 7.28B billion.
- Operating Cash Flow
- 7.89B
- Free Cash Flow
- 7.28B
- Free Cash Flow per Share
- 20.94
Dividends & Yields
Swedish Orphan Biovitrum AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 4.27%
- Earnings Yield
- 3.89%
Stock Price Statistics
- Beta
- -0.07
- 52-Week Price Change
- 71.98%
- 50-Day Moving Average
- 548.03
- 200-Day Moving Average
- 531.02
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- 1,923
Important Dates
Swedish Orphan Biovitrum AB upcoming earnings date is Feb 04, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Oct 27, 2026
- Next Earnings Date
- Feb 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Swedish Orphan Biovitrum AB as a current ratio of 0.90, with Debt / Equity ratio of 30.48%
- Current Ratio
- 0.90
- Quick Ratio
- 0.59
- Debt to Market Cap
- 0.10
- Net Debt to EBITDA
- 0.95
- Interest Coverage Ratio
- 9.68
Taxes
In the past 12 months, Swedish Orphan Biovitrum AB has paid -442.00M in taxes.
- Income Tax
- -442.00M
- Effective Tax Rate
- -13.00
Enterprise Valuation
Swedish Orphan Biovitrum AB EV to EBITDA ratio is 13.56, with an EV/FCF ratio of 25.50.
- EV to Sales
- 5.81
- EV to EBITDA
- 13.56
- EV to Free Cash Flow
- 25.50
- EV to Operating Cash Flow
- 23.55
Balance Sheet
Swedish Orphan Biovitrum AB has $1.00B in cash and marketable securities with $16.15B in debt, giving a net cash position of -$15.15B billion.
- Cash & Marketable Securities
- $1.00B
- Total Debt
- $16.15B
- Net Cash
- -$15.15B
- Net Cash Per Share
- -$42.36
- Tangible Book Value Per Share
- -$45.49
Margins
Gross margin is 68.03%, with operating margin of 31.60%, and net profit margin of 20.73%.
- Gross Margin
- 68.03%
- Operating Margin
- 31.60%
- Pretax Margin
- 25.97%
- Net Profit Margin
- 20.73%
- EBITDA Margin
- 42.86%
- EBIT Margin
- 31.59%
Analyst Forecast
The average price target for Swedish Orphan Biovitrum AB is $1,084.37, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $1,084.37
- Price Target Upside
- 20.02% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- 11.11%
- EPS Growth Forecast
- ―
